Targeting Pregnane X Receptor with a Potent Agonist-Based PROTAC to Delay Colon Cancer Relapse
Bansard, L.; Laconde, G.; Delfosse, V.; Huet, T.; Ayeul, M.; Rigal, E.; Donati, Q.; Gerbal-Chaloin, S.; Daujat-Chavanieu, M.; Legrand, B.; Chavanieu, A.; Pannequin, J.; Bourguet, W.; Amblard, M.; Pascussi, J.-M.
Show abstract
Tumor recurrence is often attributed to drug-tolerant cancer stem cells. We previously demonstrated that down regulation of the Pregnane X Receptor (PXR, NR1I2) decreases chemoresistance of cancer stem cells and prevents colorectal cancer recurrence in xenograft mouse models. These is a lack of PXR antagonists that are appropriate for clinical use. In this study, we report the design and synthesis of a novel PXR agonist-based PROTAC (JMV7048) that induces polyubiquitination and degradation of human PXR protein in an E3 CRBN ubiquitin ligase- and the 26S proteasome-dependent manner. This molecule specifically degrades PXR in colon carcinoma, hepatoma, and pancreatic cancer cell lines, but not in primary cultures of human hepatocytes. Crucially, JMV7048 decreased PXR protein expression in colon cancer stem cells and sensitized them to chemotherapy significantly delaying cancer relapse in vivo. PROTACs targeting PXR protein could thus become novel therapeutic agents to enhance cancer cell sensitivity to chemotherapy.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Targeting transcription factors through an IMiD independent zinc finger domain 97%
- Exploiting a metabolic vulnerability in brain tumour stem cells using a brain-penetrant drug with safe profile 95%
- Lowering mutant huntingtin by small molecules relieves Huntington's disease symptoms and progression 94%
Similar papers in this journal
- Citalopram exhibits immune-dependent anti-tumor effects by modulating C5aR1+ TAMs 96%
- A novel triptolide analog downregulates NF-κB and induces mitochondrial apoptosis pathways in human pancreatic cancer 94%
- USP28 deletion and small molecule inhibition destabilises c-Myc and elicits regression of squamous cell lung carcinoma 94%
Similar papers in this journal
- Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity 95%
- Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells 95%
- Enhancing Intracellular Accumulation and Target Engagement of PROTACs with Reversible Covalent Chemistry 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.